Columbia University School of Engineering and Applied Science

Promising COVID-19 Rapid Test Technology Enters Phase 1 of NIH Challenge

Highly competitive NIH RADx program selects Rover Diagnostics and biomedical engineer Sam Sia to refine and validate their low-cost, ultrafast RT PCR test.

 

Newswise — New York, NY—October 1, 2020—A promising new COVID-19 rapid-testing technology platform developed by Rover Diagnostics and Columbia Engineering has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies. The affordable, portable, and ultrafast point-of-care Rover platform provides reverse transcription polymerase chain reaction (RT-PCR) results in eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests. 

Widely used since the 1980s for both clinical and research purposes, RT-PCR has been the gold standard for molecular diagnostic testing for decades. But because traditional PCR requires typically 45 minutes and trained technicians to operate the equipment, practical clinical use of the technology has mostly been in large, centralized labs. Because Rover’s PCR is very portable (about two pounds) and can be used by anyone, it will be targeted to locations where rapid turnaround results are important: for example, at pharmacies, transportation hubs, public events, and at companies screening employees coming back to work. 

The platform was developed by Rover Diagnostics, a biotech start-up co-founded in 2018 by Biomedical Engineering Professor Sam Sia and serial tech entrepreneur Mark Fasciano, Rover’s CEO. The system uses sample preparation techniques developed at Sia’s lab, combined with a new approach to thermal cycling, bypassing the standard approach of Peltier device—a semiconductor that heats and cools the sample from outside the vial with radiant heat.  Instead, Rover’s system uses a photothermal process that relies on nanoparticles to generate heat from inside. 

“We were determined to develop a testing platform for all kinds of viruses that is cheap, reliable, and accessible to everyone,” says Sia, an innovator in point-of-care blood tests, wearable sensors, and implantable devices. “With Rover, we can now perform thermal cycling, which is the backbone of high-performing DNA and RNA testing, several times faster.” 

The timing for Sia and Fasciano was fortuitous; Rover’s first prototype was completed just months before COVID-19 hit. The team quickly focused the Rover platform on the novel coronavirus and set the requirements to design as inexpensive and fast a COVID-19 test as possible. 

“Prior to COVID, our mission to advance testing of infectious diseases was important, but the pandemic has intensified our efforts tenfold,” says Fasciano, a computer scientist-turned software and biotech entrepreneur. “Our rapid progress towards fast, cheap, ubiquitous testing has been possible largely through the unprecedented level of collaboration between Columbia Engineering and Rover, and the 24/7 dedication of our teams.” 

In addition to COVID-19, Rover’s platform is designed to test for a broad range of infectious diseases including flu, strep, and other viruses that require fast diagnosis. Its targeted sensitivity is higher than other types of tests such as isothermal, antigen, and CRISPR. And is slated to be much faster than any other PCR test. 

Sia and Fasciano now have a month to validate their platform. NIH launched the RADx initiative on April 29, 2020, just days after receiving an emergency supplemental appropriation of $1.5 billion from Congress. One arm of the RADx initiative supports innovative technologies that would make millions of rapid COVID-19 tests per week available to Americans by the fall. The call from NIH has received more than 700 applications. 

More than 120 of the best concepts, including Rover’s, were selected to enter an intense one-week “shark-tank” technology evaluation process. The Rover team is among the 33 companies that have so far made the cut and advance to Phase 1, a rigorous four-week period of initial technology validation for scale up, manufacturing, and delivery to the marketplace. 

The Rover team is optimistic about continuing the pace of progress. Says Sia, “We are expanding our testing of clinical samples and bringing together additional resources and expertise to finalize the design and speed to manufacturing. The NIH RADx initiative is accelerating our progress to bring the fast PCR platform to the widest possible good.” 

This project is supported by the NIH Rapid Acceleration of Diagnostics (RADx) Tech program and has been funded in whole or in part with Federal funds from the National Heart, Lung and Blood Institute, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Grant No. U54HL143541. 

### 

LINKS:http://engineering.columbia.edu/
https://www.nih.gov/research-training/medical-research-initiatives/radx
http://roverdx.com
https://bme.columbia.edu/
https://engineering.columbia.edu/faculty/sam-sia
https://www.linkedin.com/in/markfasciano/ 

### 

Columbia Engineering
Columbia Engineering, based in New York City, is one of the top engineering schools in the U.S. and one of the oldest in the nation. Also known as The Fu Foundation School of Engineering and Applied Science, the School expands knowledge and advances technology through the pioneering research of its more than 220 faculty, while educating undergraduate and graduate students in a collaborative environment to become leaders informed by a firm foundation in engineering. The School’s faculty are at the center of the University’s cross-disciplinary research, contributing to the Data Science Institute, Earth Institute, Zuckerman Mind Brain Behavior Institute, Precision Medicine Initiative, and the Columbia Nano Initiative. Guided by its strategic vision, “Columbia Engineering for Humanity,” the School aims to translate ideas into innovations that foster a sustainable, healthy, secure, connected, and creative humanity. 

Rover Diagnostics
Rover Diagnostics was founded in 2018 by Samuel Sia and Mark Fasciano in collaboration with Columbia University. Based in New York City, Rover’s primary mission is to help meet the urgent global need for a cost-effective, highly sensitive, mass-produced point-of-care COVID-19 instrument and test kit system.

 




Filters close

Showing results

2130 of 4581
Released: 15-Jan-2021 8:55 AM EST
The First Dose of the Pfizer Vaccine Gives About 50% COVID Protection, Not 91% Claimed by Those Who Want to Speed Up Immunization
Newswise

The NEJM paper actually states that the efficacy between the first and second doses was found to be 52 percent when given 21 days apart. After the second dose, the efficacy raises to 95 percent.

Released: 15-Jan-2021 8:20 AM EST
Houston Methodist study finds males of all ages more affected by COVID-19 than females
Houston Methodist

A new Houston Methodist study found males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age. The peer-reviewed observational study appears in PLOS ONE, a multidisciplinary journal published by the Public Library of Science.

Released: 15-Jan-2021 8:20 AM EST
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Ivermectin is Now a Therapeutic Option for Doctors & Prescribers

Newswise: Studying and Treating COVID-19’s Long-Term Impact
Released: 14-Jan-2021 6:05 PM EST
Studying and Treating COVID-19’s Long-Term Impact
Rush University Medical Center

The CDC is funding a Rush-led effort in which 8 academic medical centers will track the clinical, physical and mental functioning -- including neuro-cognition and fatigue – of nearly 5000 COVID patients for two years to better assess the long-term outcomes of the disease.

Newswise: Potential COVID-19 Drug Is Successful in Lab Study
Released: 14-Jan-2021 5:20 PM EST
Potential COVID-19 Drug Is Successful in Lab Study
Rush University Medical Center

A new potential therapy for COVID-19 developed by researchers at Rush University Medical Center has shown success in preventing the disease’s symptoms in mice.

Newswise: S&T Joins Coalition Seeking to ‘Flush’ out COVID-19 in Wastewater
Released: 14-Jan-2021 2:40 PM EST
S&T Joins Coalition Seeking to ‘Flush’ out COVID-19 in Wastewater
Homeland Security's Science And Technology Directorate

S&T is working with NIST and the University of Louisville to develop guidelines to standardize Wastewater-Based Epidemiology testing methods nationwide.

Released: 14-Jan-2021 12:40 PM EST
Perceptions of police using PPE during the pandemic
Simon Fraser University

A Simon Fraser University study on public perceptions of police officers wearing personal protective equipment (PPE) during the current pandemic finds that most PPE renders positive perceptions of police, while some equipment, including full-face respirator masks, may be viewed more negatively.

Released: 14-Jan-2021 12:05 PM EST
Population density and virus strains will affect how regions can resume normal life
University of Wisconsin-Madison

As a new, apparently more transmissible version of the virus that causes COVID-19 has appeared in several countries, new research finds that the transmissibility of viral strains and the population density of a region will play big roles in how vaccination campaigns can help towns and cities return to more normal activities. The findings suggest that directing vaccines toward densely populated counties would help to interrupt transmission of the disease.

13-Jan-2021 12:05 PM EST
Study shows sharp decline in cancer screenings and diagnoses during the first COVID-19 surge
Dana-Farber Cancer Institute

In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and Women’s Cancer Center document a substantial decline in cancer and precancer diagnoses at the Northeast’s largest health care system during the first peak of the pandemic because of a drop in the number of cancer screening tests performed.

Released: 14-Jan-2021 10:50 AM EST
The Richer You are, The More Likely You’ll Social Distance, Study Finds
Johns Hopkins University

The higher a person’s income, the more likely they were to protect themselves at the early stages of the Covid-19 pandemic in the United States, Johns Hopkins University economists find. When it comes to adopting behaviors including social distancing and mask wearing, the team detected a striking link to their financial well-being. People who made around $230,000 a year were as much as 54% more likely to increase these types of self-protective behaviors compared to people making about $13,000.


Showing results

2130 of 4581

close
1.18002